Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ethyl N-[(2-{[(4-{n'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1h-benzimidazol-5-yl)carbonyl]-n-pyridin-2-yl-beta-alaninate
2. Pradaxa (tn)
3. Dsstox_cid_31470
4. Dsstox_rid_97355
5. Dsstox_gsid_57681
6. Schembl505829
7. Dabigatran Etexilate (usan/inn)
8. Tox21_113924
9. Bdbm50432209
10. S2154
11. Stl450990
12. Stl483396
13. Ncgc00262929-01
14. Cas-211915-06-9
15. D07144
16. Ab01274780-01
17. Ab01274780_02
18. A815191
19. 3-[[[2-[[4-[(e)-amino-[hexoxy(oxo)methyl]iminomethyl]anilino]methyl]-1-methyl-5-benzimidazolyl]-oxomethyl]-(2-pyridinyl)amino]propanoic Acid Ethyl Ester
20. Ethyl 3-[[2-[[[4-[(e)-n'-hexoxycarbonylcarbamimidoyl]phenyl]amino]methyl]-1-methyl-benzimidazol-5-yl]carbonyl-pyridin-2-yl-amino]propanoate
21. Ethyl N-[(2-{[(4-{n-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1h-benzimidazol-5-yl)carbonyl]-n-pyridin-2-yl-beta-alaninate
| Molecular Weight | 627.7 g/mol |
|---|---|
| Molecular Formula | C34H41N7O5 |
| XLogP3 | 5.7 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 17 |
| Exact Mass | 627.31691743 g/mol |
| Monoisotopic Mass | 627.31691743 g/mol |
| Topological Polar Surface Area | 154 Ų |
| Heavy Atom Count | 46 |
| Formal Charge | 0 |
| Complexity | 1000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Pradaxa 75 mg
- Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.
Pradaxa 110 mg
- Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age 75 years; heart failure (NYHA Class II); diabetes mellitus; hypertension.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
Pradaxa 150 mg
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age 75 years; heart failure (NYHA Class II); diabetes mellitus; hypertension.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
B01AE07
ABOUT THIS PAGE
A 211915-06-9 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 211915-06-9, including repackagers and relabelers. The FDA regulates 211915-06-9 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 211915-06-9 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A 211915-06-9 supplier is an individual or a company that provides 211915-06-9 active pharmaceutical ingredient (API) or 211915-06-9 finished formulations upon request. The 211915-06-9 suppliers may include 211915-06-9 API manufacturers, exporters, distributors and traders.
211915-06-9 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 211915-06-9 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 211915-06-9 GMP manufacturer or 211915-06-9 GMP API supplier for your needs.
A 211915-06-9 CoA (Certificate of Analysis) is a formal document that attests to 211915-06-9's compliance with 211915-06-9 specifications and serves as a tool for batch-level quality control.
211915-06-9 CoA mostly includes findings from lab analyses of a specific batch. For each 211915-06-9 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
211915-06-9 may be tested according to a variety of international standards, such as European Pharmacopoeia (211915-06-9 EP), 211915-06-9 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (211915-06-9 USP).
LOOKING FOR A SUPPLIER?
